Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	21 October 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Trustee	
Date of change	30 June 2017	
No. of securities held prior to change	Brett and Michelle Mitchell <mitchell a="" c="" family="" spring=""> 9,458,889 Ordinary Shares 8,000,000 Performance Rights 1,500,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,500,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017 800,000 Unlisted Options exercisable at \$0.20 each on or before 30 June 2017 Brett and Michelle Mitchell <lefthanders a="" c="" fund="" super=""> 1,735,005 Ordinary Shares 2,000,000 Performance Rights 1,000,000 Unlisted Options exercisable at \$0.025 each on or before 30 June 2017 1,000,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017</lefthanders></mitchell>	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Unlisted Options exercised into Ordinary Shares	
Number acquired	5,000,000 Ordinary Shares (converted from 2,500,000 unlisted options exercisable at 2.5c each and 2,500,000 unlisted options exercisable at 4c each)	
Number disposed	800,000 Unlisted Options exercisable at \$0.20 each have lapsed unexercised due to expiry date being 30 June 2017	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$162,500	
No. of securities held after change	Brett and Michelle Mitchell <mitchell a="" c="" family="" spring=""> 12,458,889 Ordinary Shares 8,000,000 Performance Rights Brett and Michelle Mitchell <lefthanders a="" c="" fund="" super=""> 3,735,005 Ordinary Shares 2,000,000 Performance Rights</lefthanders></mitchell>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of 2,500,000 unlisted options exercisable at 2.5c each and 2,500,000 unlisted options exercisable at 4c each	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

⁺ See chapter 19 for defined terms.

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this	
provided?	

01/01/2011

⁺ See chapter 19 for defined terms.